82 related articles for article (PubMed ID: 8453585)
41. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo DL; Duffey PL; Young RC; Hubbard SM; Ihde DC; Glatstein E; Phares JC; Jaffe ES; Urba WJ; DeVita VT
J Clin Oncol; 1992 Feb; 10(2):210-8. PubMed ID: 1732422
[TBL] [Abstract][Full Text] [Related]
42. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
Shahidi M; Kamangari N; Ashley S; Cunningham D; Horwich A
Radiother Oncol; 2006 Jan; 78(1):1-5. PubMed ID: 16309770
[TBL] [Abstract][Full Text] [Related]
43. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
44. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
46. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
[TBL] [Abstract][Full Text] [Related]
47. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
[TBL] [Abstract][Full Text] [Related]
48. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
49. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
50. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial.
Mauch PM; Canellos GP; Shulman LN; Silver B; Tarbell NJ; Come S; Rabin MS; Coleman CN
J Clin Oncol; 1995 Apr; 13(4):947-52. PubMed ID: 7707123
[TBL] [Abstract][Full Text] [Related]
51. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease.
Tourani JM; Levy R; Colonna P; Desablens B; Leprise PY; Guilhot F; Brahimi S; Belhani M; Ifrah N; Sensebe L
J Clin Oncol; 1992 Jul; 10(7):1086-94. PubMed ID: 1607915
[TBL] [Abstract][Full Text] [Related]
52. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease.
Zagars G; Rubin P
Cancer; 1985 Aug; 56(4):864-73. PubMed ID: 4016677
[TBL] [Abstract][Full Text] [Related]
53. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
54. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages.
Andrieu JM; Jais JP; Colonna P; Desablens B; Brière J; François S; Harousseau JL; Casassus P; Lemevel A; Le Prisé PY; Ghandour C; Guilhot F; Lejeune F
Ann Oncol; 1998 Feb; 9(2):195-203. PubMed ID: 9553666
[TBL] [Abstract][Full Text] [Related]
55. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
Koontz BF; Kirkpatrick JP; Clough RW; Prosnitz RG; Gockerman JP; Moore JO; Prosnitz LR
J Clin Oncol; 2006 Feb; 24(4):605-11. PubMed ID: 16446333
[TBL] [Abstract][Full Text] [Related]
56. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
[TBL] [Abstract][Full Text] [Related]
57. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
58. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
[TBL] [Abstract][Full Text] [Related]
59. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification.
Ferry JA; Linggood RM; Convery KM; Efird JT; Eliseo R; Harris NL
Cancer; 1993 Jan; 71(2):457-63. PubMed ID: 8422639
[TBL] [Abstract][Full Text] [Related]
60. Late relapses in Hodgkin disease.
Kanofsky JR; Golomb HM; Vardiman JE; Sweet DL; Ultmann JE
Am J Hematol; 1981; 10(1):31-6. PubMed ID: 7258180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
